Ottens Andrew K, Kobeissy Firas H, Fuller Brian F, Liu Ming Chen, Oli Monika W, Hayes Ronald L, Wang Kevin K W
Department of Psychiatry, Center for Neuroproteomics and Biomarkers Research at the McKnight Brain Institute of the University of Florida, PO Box 100256, Gainesville, FL 32610, USA.
Prog Brain Res. 2007;161:401-18. doi: 10.1016/S0079-6123(06)61029-7.
Neuroproteomics entails wide-scope study of the nervous system proteome in both its content and dynamics. The field employs high-end analytical mass spectrometry and novel high-throughput antibody approaches to characterize as many proteins as possible. The most common application has been differential analysis to identify a limited set of highly dynamic proteins associated with injury, disease, or other altered states of the nervous system. Traumatic brain injury (TBI) is an important neurological condition where neuroproteomics has revolutionized the characterization of protein dynamics, leading to a greater understanding of post-injury biochemistry. Further, proteins of altered abundance or post-translational modifications identified by neuroproteomic studies are candidate biochemical markers of TBI. This chapter explores the use of neuroproteomics in the study of TBI and the validation of identified putative biomarkers for subsequent clinical translation into novel injury diagnostics.
神经蛋白质组学需要对神经系统蛋白质组的组成和动态变化进行广泛研究。该领域采用高端分析质谱和新型高通量抗体方法来尽可能多地鉴定蛋白质。最常见的应用是差异分析，以识别与损伤、疾病或神经系统其他改变状态相关的一组有限的高动态蛋白质。创伤性脑损伤（TBI）是一种重要的神经系统疾病，神经蛋白质组学在其中彻底改变了蛋白质动态变化的特征描述，从而使人们对损伤后生物化学有了更深入的了解。此外，通过神经蛋白质组学研究鉴定出的丰度改变或翻译后修饰的蛋白质是TBI的候选生化标志物。本章探讨了神经蛋白质组学在TBI研究中的应用，以及对已鉴定的假定生物标志物进行验证，以便随后临床转化为新型损伤诊断方法。
